http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 04 Jun 2026 06:09:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Jun+04/26601978.html si-local-file:///var/storage/secattach/20260604/26601978.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Jun+04/26601978.html Thu, 04 Jun 2026 06:09:00 -0400 O.00551852 PHAR PHARM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Jun+04/26601978.html si-local-file:///var/storage/secattach/20260604/26601978.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Jun+04/26601978.html Thu, 04 Jun 2026 06:09:00 -0400 O.00551852 PHAR PHARM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Jun+04/26601978.html si-local-file:///var/storage/secattach/20260604/26601978.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+Jun+04/26601978.html Thu, 04 Jun 2026 06:09:00 -0400 O.00551852 PHAR PHARM http://www.streetinsider.com/Press+Releases/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><b>If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency </b></li><li style="margin-bottom:6pt; text-align:left;"><b>Supplemental New Drug Application (sNDA) resubmission seeks approval for 40 mg and 50 mg twice-daily dosing</b></li><li style="margin-bottom:6pt; text-align:left;"><b>Separate sNDA for lower weight pediatric patients planned for second half 2026</b><br/><br/></li></ul> <p align="justify"><b>Leiden, the Netherlands, June 4, 2026: </b>Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a http://www.streetinsider.com/Press+Releases/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html Thu, 04 Jun 2026 01:00:00 -0400 A.06822034 O.00551852 O.20026344 PHAR PHARM PHARM http://www.streetinsider.com/Press+Releases/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><b>If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency </b></li><li style="margin-bottom:6pt; text-align:left;"><b>Supplemental New Drug Application (sNDA) resubmission seeks approval for 40 mg and 50 mg twice-daily dosing</b></li><li style="margin-bottom:6pt; text-align:left;"><b>Separate sNDA for lower weight pediatric patients planned for second half 2026</b><br/><br/></li></ul> <p align="justify"><b>Leiden, the Netherlands, June 4, 2026: </b>Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a http://www.streetinsider.com/Press+Releases/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html Thu, 04 Jun 2026 01:00:00 -0400 A.06822034 O.00551852 O.20026344 PHAR PHARM PHARM http://www.streetinsider.com/Press+Releases/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><b>If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency </b></li><li style="margin-bottom:6pt; text-align:left;"><b>Supplemental New Drug Application (sNDA) resubmission seeks approval for 40 mg and 50 mg twice-daily dosing</b></li><li style="margin-bottom:6pt; text-align:left;"><b>Separate sNDA for lower weight pediatric patients planned for second half 2026</b><br/><br/></li></ul> <p align="justify"><b>Leiden, the Netherlands, June 4, 2026: </b>Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a http://www.streetinsider.com/Press+Releases/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html Thu, 04 Jun 2026 01:00:00 -0400 A.06822034 O.00551852 O.20026344 PHAR PHARM PHARM http://www.streetinsider.com/Press+Releases/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><b>If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency </b></li><li style="margin-bottom:6pt; text-align:left;"><b>Supplemental New Drug Application (sNDA) resubmission seeks approval for 40 mg and 50 mg twice-daily dosing</b></li><li style="margin-bottom:6pt; text-align:left;"><b>Separate sNDA for lower weight pediatric patients planned for second half 2026</b><br/><br/></li></ul> <p align="justify"><b>Leiden, the Netherlands, June 4, 2026: </b>Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a http://www.streetinsider.com/Press+Releases/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html Thu, 04 Jun 2026 01:00:00 -0400 A.06822034 O.00551852 O.20026344 PHAR PHARM PHARM http://www.streetinsider.com/Press+Releases/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><b>If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency </b></li><li style="margin-bottom:6pt; text-align:left;"><b>Supplemental New Drug Application (sNDA) resubmission seeks approval for 40 mg and 50 mg twice-daily dosing</b></li><li style="margin-bottom:6pt; text-align:left;"><b>Separate sNDA for lower weight pediatric patients planned for second half 2026</b><br/><br/></li></ul> <p align="justify"><b>Leiden, the Netherlands, June 4, 2026: </b>Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a http://www.streetinsider.com/Press+Releases/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html Thu, 04 Jun 2026 01:00:00 -0400 A.06822034 O.00551852 O.20026344 PHAR PHARM PHARM http://www.streetinsider.com/Press+Releases/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><b>If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency </b></li><li style="margin-bottom:6pt; text-align:left;"><b>Supplemental New Drug Application (sNDA) resubmission seeks approval for 40 mg and 50 mg twice-daily dosing</b></li><li style="margin-bottom:6pt; text-align:left;"><b>Separate sNDA for lower weight pediatric patients planned for second half 2026</b><br/><br/></li></ul> <p align="justify"><b>Leiden, the Netherlands, June 4, 2026: </b>Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a http://www.streetinsider.com/Press+Releases/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html Thu, 04 Jun 2026 01:00:00 -0400 A.06822034 O.00551852 O.20026344 PHAR PHARM PHARM http://www.streetinsider.com/Globe+Newswire/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><b>If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency </b></li><li style="margin-bottom:6pt; text-align:left;"><b>Supplemental New Drug Application (sNDA) resubmission seeks approval for 40 mg and 50 mg twice-daily dosing</b></li><li style="margin-bottom:6pt; text-align:left;"><b>Separate sNDA for lower weight pediatric patients planned for second half 2026</b><br/><br/></li></ul> <p align="justify"><b>Leiden, the Netherlands, June 4, 2026: </b>Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a http://www.streetinsider.com/Globe+Newswire/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html Thu, 04 Jun 2026 01:00:00 -0400 A.06822034 O.00551852 O.20026344 PHAR PHARM PHARM http://www.streetinsider.com/Globe+Newswire/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><b>If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency </b></li><li style="margin-bottom:6pt; text-align:left;"><b>Supplemental New Drug Application (sNDA) resubmission seeks approval for 40 mg and 50 mg twice-daily dosing</b></li><li style="margin-bottom:6pt; text-align:left;"><b>Separate sNDA for lower weight pediatric patients planned for second half 2026</b><br/><br/></li></ul> <p align="justify"><b>Leiden, the Netherlands, June 4, 2026: </b>Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a http://www.streetinsider.com/Globe+Newswire/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html Thu, 04 Jun 2026 01:00:00 -0400 A.06822034 O.00551852 O.20026344 PHAR PHARM PHARM http://www.streetinsider.com/Globe+Newswire/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><b>If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency </b></li><li style="margin-bottom:6pt; text-align:left;"><b>Supplemental New Drug Application (sNDA) resubmission seeks approval for 40 mg and 50 mg twice-daily dosing</b></li><li style="margin-bottom:6pt; text-align:left;"><b>Separate sNDA for lower weight pediatric patients planned for second half 2026</b><br/><br/></li></ul> <p align="justify"><b>Leiden, the Netherlands, June 4, 2026: </b>Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a http://www.streetinsider.com/Globe+Newswire/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html Thu, 04 Jun 2026 01:00:00 -0400 A.06822034 O.00551852 O.20026344 PHAR PHARM PHARM http://www.streetinsider.com/Globe+Newswire/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><b>If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency </b></li><li style="margin-bottom:6pt; text-align:left;"><b>Supplemental New Drug Application (sNDA) resubmission seeks approval for 40 mg and 50 mg twice-daily dosing</b></li><li style="margin-bottom:6pt; text-align:left;"><b>Separate sNDA for lower weight pediatric patients planned for second half 2026</b><br/><br/></li></ul> <p align="justify"><b>Leiden, the Netherlands, June 4, 2026: </b>Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a http://www.streetinsider.com/Globe+Newswire/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html Thu, 04 Jun 2026 01:00:00 -0400 A.06822034 O.00551852 O.20026344 PHAR PHARM PHARM http://www.streetinsider.com/Globe+Newswire/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><b>If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency </b></li><li style="margin-bottom:6pt; text-align:left;"><b>Supplemental New Drug Application (sNDA) resubmission seeks approval for 40 mg and 50 mg twice-daily dosing</b></li><li style="margin-bottom:6pt; text-align:left;"><b>Separate sNDA for lower weight pediatric patients planned for second half 2026</b><br/><br/></li></ul> <p align="justify"><b>Leiden, the Netherlands, June 4, 2026: </b>Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a http://www.streetinsider.com/Globe+Newswire/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html Thu, 04 Jun 2026 01:00:00 -0400 A.06822034 O.00551852 O.20026344 PHAR PHARM PHARM http://www.streetinsider.com/Globe+Newswire/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html <ul type="disc"><li style="margin-bottom:6pt; text-align:left;"><b>If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency </b></li><li style="margin-bottom:6pt; text-align:left;"><b>Supplemental New Drug Application (sNDA) resubmission seeks approval for 40 mg and 50 mg twice-daily dosing</b></li><li style="margin-bottom:6pt; text-align:left;"><b>Separate sNDA for lower weight pediatric patients planned for second half 2026</b><br/><br/></li></ul> <p align="justify"><b>Leiden, the Netherlands, June 4, 2026: </b>Pharming Group (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its resubmitted supplemental New Drug Application (sNDA) seeking approval for Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a http://www.streetinsider.com/Globe+Newswire/Pharming+announces+U.S.+FDA+acceptance+of+sNDA+resubmission+for+Joenja%C2%AE+%28leniolisib%29+to+treat+children+aged+4+to+11+years+with+APDS/26601280.html Thu, 04 Jun 2026 01:00:00 -0400 A.06822034 O.00551852 O.20026344 PHAR PHARM PHARM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+May+28/26563382.html si-local-file:///var/storage/secattach/20260528/26563382.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+May+28/26563382.html Thu, 28 May 2026 10:53:00 -0400 O.00551852 PHAR PHARM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+May+28/26563382.html si-local-file:///var/storage/secattach/20260528/26563382.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+May+28/26563382.html Thu, 28 May 2026 10:53:00 -0400 O.00551852 PHAR PHARM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+May+28/26563382.html si-local-file:///var/storage/secattach/20260528/26563382.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+May+28/26563382.html Thu, 28 May 2026 10:53:00 -0400 O.00551852 PHAR PHARM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+May+22/26542113.html si-local-file:///var/storage/secattach/20260522/26542113.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+May+22/26542113.html Fri, 22 May 2026 16:26:00 -0400 O.00551852 PHAR PHARM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+May+22/26542113.html si-local-file:///var/storage/secattach/20260522/26542113.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+May+22/26542113.html Fri, 22 May 2026 16:26:00 -0400 O.00551852 PHAR PHARM http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+May+22/26542113.html si-local-file:///var/storage/secattach/20260522/26542113.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Pharming+Group+N.V.+++++++For%3A+May+22/26542113.html Fri, 22 May 2026 16:26:00 -0400 O.00551852 PHAR PHARM http://www.streetinsider.com/Analyst+PT+Change/Pharming+Group+%28PHAR%29+PT+Lowered+to+%2440+at+Oppenheimer/26458168.html Oppenheimer lowered its price target on Pharming Group (NASDAQ: PHAR) to $40.00 (from $41.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Pharming+Group+%28PHAR%29+PT+Lowered+to+%2440+at+Oppenheimer/26458168.html Fri, 08 May 2026 08:14:37 -0400 PHAR http://www.streetinsider.com/New+Coverage/Canaccord+Starts+Pharming+Group+%28PHAR%29+at+Buy%2C+PT+%2437/26297143.html <p>Canaccord analyst Whitney Ijem initiates coverage on Pharming Group (NASDAQ: PHAR) with a Buy rating and a price target of $37.00.</p><p>For an analyst ratings summary and ratings history on Pharming Group <a href="http://www.streetinsider.com/rating_history.php?q=PHAR">click here</a>. For more ratings news on Pharming Group <a href="http://www.streetinsider.com/stock_lookup_news.php?q=PHAR&amp;type=analyst">click here</a>.</p><p>Shares of Pharming Group closed at $16.98 yesterday.</p> http://www.streetinsider.com/New+Coverage/Canaccord+Starts+Pharming+Group+%28PHAR%29+at+Buy%2C+PT+%2437/26297143.html Fri, 10 Apr 2026 05:19:43 -0400 PHAR http://www.streetinsider.com/Hot+New+Coverage/Canaccord+Starts+Pharming+Group+%28PHAR%29+at+Buy%2C+PT+%2437/26297143.html <p>Canaccord analyst Whitney Ijem initiates coverage on Pharming Group (NASDAQ: PHAR) with a Buy rating and a price target of $37.00.</p><p>For an analyst ratings summary and ratings history on Pharming Group <a href="http://www.streetinsider.com/rating_history.php?q=PHAR">click here</a>. For more ratings news on Pharming Group <a href="http://www.streetinsider.com/stock_lookup_news.php?q=PHAR&amp;type=analyst">click here</a>.</p><p>Shares of Pharming Group closed at $16.98 yesterday.</p> http://www.streetinsider.com/Hot+New+Coverage/Canaccord+Starts+Pharming+Group+%28PHAR%29+at+Buy%2C+PT+%2437/26297143.html Fri, 10 Apr 2026 05:19:43 -0400 PHAR http://www.streetinsider.com/Analyst+PT+Change/Pharming+Group+%28PHAR%29+PT+Lowered+to+%2441+at+Oppenheimer/26156712.html Oppenheimer lowered its price target on Pharming Group (NASDAQ: PHAR) to $41.00 (from $42.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Pharming+Group+%28PHAR%29+PT+Lowered+to+%2441+at+Oppenheimer/26156712.html Fri, 13 Mar 2026 08:28:29 -0400 PHAR